Oxytocin: nootropics and compounds | sci-wiki

Oxytocin

Oxytocin is a nine-amino-acid neuropeptide made in the hypothalamus and released from the posterior pituitary, best known for driving uterine contraction in labor and milk ejection during nursing, and for its role in social bonding and affiliation. Its release during suckling and birth is a rare biological positive-feedback loop, amplified within the hypothalamus itself, and the neurons that make it synchronize into coordinated bursts to produce the pulsatile milk-ejection reflex. As an intranasal research tool it has generated a large human literature on trust and social cognition, though that work is tempered by a replication debate and by questions about how much intranasal oxytocin reaches the brain, and large trials in autism have been largely negative.

6 outlets

Peptide

Demoxytocin

Demoxytocin, also known as desamino-oxytocin or deaminooxytocin, is a synthetic analogue of the hormone oxytocin. It is a modified peptide in which the free amino group at one end of the oxytocin molecule has been removed, a change that makes it more resistant to breakdown in the body and gives it a longer, stronger action. Like oxytocin, it is an oxytocic drug that stimulates uterine contractions and milk release, and it has been used to help induce labor, support lactation, and manage breast engorgement. It is notable for being given as a buccal tablet that dissolves in the mouth.

reference

Nootropic

LIT-001

LIT-001 is the first non-peptide oxytocin receptor agonist that reaches the brain and changes behaviour after an ordinary injection into the body, rather than having to be delivered into the skull. Oxytocin itself is a therapeutic dead end for brain use for three separate reasons, and this molecule was built to defeat all three at once. It has never been given to a human being.

reference

Entactogen

MDMA

MDMA (3,4-methylenedioxymethamphetamine) is a synthetic entactogen of the substituted amphetamine family that produces emotional closeness, empathy, and euphoria, effects mediated principally by carrier-mediated release and reuptake inhibition of serotonin along with dopamine and norepinephrine, with downstream involvement of oxytocin and 5-HT1A signaling. Translational work indicates that MDMA enhances the extinction of conditioned fear and modulates emotional memory circuits, reducing amygdala reactivity while strengthening amygdala-hippocampal connectivity, and this effect is abolished by serotonin transporter blockade, underscoring the central role of serotonin release. On this rationale, MDMA-assisted therapy advanced to randomized, placebo-controlled phase 3 trials for post-traumatic stress disorder, where it produced significant reductions in symptom severity and functional impairment. Its recognized hazards include acute hyperthermia and cardiovascular strain, potential serotonergic neurotoxicity at high or repeated doses, and 5-HT2B-linked cardiac valve risk associated with chronic exposure.

reference